HeartBeam Receives FDA Breakthrough Device Designation For Its HeartBeam System For Assessing Potential Heart Attacks At Home

HeartBeam Named Contributing Partner In Launch Of EXIT-CVD Research Project, Co-Funded By European Union Innovative Health Initiative And Industry Partners

HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortiumHeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studiesHEART-CHECK

HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System

HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.

HeartBeam shares are trading higher after the company announced it received the FDA Breakthrough Device Designation for the HeartBeam System as a tool for assessing potential heart attacks at home.

Dow Gains 100 Points; ISM Services PMI Falls In September

U.S. stocks rose Monday: Dow +0.2%, S&P 500 +0.62%, Nasdaq +0.84%. Materials led; ISM services PMI slipped to 54.9. Oil fell 1%.